Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Ligelizumab Maintains Urticaria Control For Up to 1 Year

Publish date:: April 29, 2019

Key clinical point: The anti-IgE monoclonal antibody controlled hives and other symptoms well for up to a year.

Major finding: About 75% of the cohort experienced complete disease control at least once during the study.

Study details: The extension study comprised 96 patients treated with ligelizumab for 12 weeks in a phase 2 study.

Disclosures: Dr. Baker is a clinical trials investigator for Novartis, which is developing ligelizumab.

Citation:

Baker D et al. AAD 2019, Session S034.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

Must Reads in Dermatology

Swedish registry study finds atopic dermatitis significantly associated with autoimmune diseases,

Study results support screening rosacea patients for cardiometabolic disease,

Phase 1 study: Beta-blocker may improve melanoma treatment response,

Baricitinib reduces adult atopic dermatitis severity in phase 3 study,

New lupus classification criteria perform well in children, young adults,